PRELIMINARY SAFETY, EFFICACY AND PHARMACOKINETICS (PK) RESULTS OF KN026 (A HER2 BISPECIFIC ANTIBODY) MONOTHERAPY IN ADVANCED SOLID TUMOR PATIENTS WITH HER2 EXPRESSION

BACKGROUND: KN026 is a novel bispecific antibody and simultaneously binds to two distinct HER2 epitopes which are the same domains as trastuzumab (ECD4) and pertuzumab (ECD2). It showed higher maximal binding than monospecific HER2 antibodies and favors that crosslinking of HER2 receptors could enha...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Ting, Lv, Yuan, Sun, Jie, Peng, Jianjian, Li, Jingqiu, Li, Xionghui, Guo, Baohong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10370438/
http://dx.doi.org/10.1093/abt/tbad014.006

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10370438/
http://dx.doi.org/10.1093/abt/tbad014.006

Ejemplares similares